An international trial is examining the efficacy of a vaccine for C. difficile, the gut-destroying bacterium that is particularly dangerous to seniors.
Biogen Idec, which was heralded last week for results of an Alzheimer's drug trial, has shortened its name and chosen a new logo. It will now be known as Biogen (Nasdag: BIIB).
Back in June, I declared medication to be the long-term care topic of the summer. But this week, a different topic has stolen the spotlight: Clostridium difficile.